GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (TSX:PMN) » Definitions » EV-to-EBITDA

ProMIS Neurosciences (TSX:PMN) EV-to-EBITDA : -2.20 (As of May. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ProMIS Neurosciences's enterprise value is C$38.64 Mil. ProMIS Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-17.56 Mil. Therefore, ProMIS Neurosciences's EV-to-EBITDA for today is -2.20.

The historical rank and industry rank for ProMIS Neurosciences's EV-to-EBITDA or its related term are showing as below:

TSX:PMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.65   Med: -5.11   Max: 0.22
Current: -2.01

During the past 13 years, the highest EV-to-EBITDA of ProMIS Neurosciences was 0.22. The lowest was -16.65. And the median was -5.11.

TSX:PMN's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs TSX:PMN: -2.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), ProMIS Neurosciences's stock price is C$6.00. ProMIS Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-2.017. Therefore, ProMIS Neurosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


ProMIS Neurosciences EV-to-EBITDA Historical Data

The historical data trend for ProMIS Neurosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences EV-to-EBITDA Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.25 -5.23 -3.87 -1.76 -0.70

ProMIS Neurosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 -1.79 -1.57 -1.18 -0.70

Competitive Comparison of ProMIS Neurosciences's EV-to-EBITDA

For the Biotechnology subindustry, ProMIS Neurosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's EV-to-EBITDA falls into.



ProMIS Neurosciences EV-to-EBITDA Calculation

ProMIS Neurosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=38.640/-17.558
=-2.20

ProMIS Neurosciences's current Enterprise Value is C$38.64 Mil.
ProMIS Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-17.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProMIS Neurosciences  (TSX:PMN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ProMIS Neurosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.00/-2.017
=At Loss

ProMIS Neurosciences's share price for today is C$6.00.
ProMIS Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.017.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


ProMIS Neurosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences (TSX:PMN) Business Description

Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.